FDA Review Finds No Increased Risk of MI With Dabigatran (Pradaxa)FDA Review Finds No Increased Risk of MI With Dabigatran (Pradaxa)

The latest FDA study to tackle dabigatran's risk/benefit profile also found fewer ischemic strokes, intracranial bleeds, and deaths with dabigatran but fewer major GI bleeds with warfarin. News Alerts
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news